Source: PR Newswire ALPHAEON Corporation (www.alphaeon.com) today announced that its wholly-owned subsidiary, Evolus Inc., submitted a Biologics License Application (BLA) for DWP-450, a Botulinum toxin Type A, to the U.S. Food and Drug Administration (FDA) seeking approval for the treatment of adult patients with glabellar lines, also known as "frown…...